TOS Urges FDA to be Fair when Judging New Evidence-Based Treatment Approaches for Obesity

On July 15, 2010, the Food & Drug Administration (FDA) and its Advisory Committee on Endocrinologic and Metabolic Drugs held the first of three meetings - initiating a six-month period where the FDA will examine new pharmaceutical treatment avenues for those who struggle with their weight. The focus of the July 15 advisory committee meeting was QNEXA, a new weight loss drug developed by VIVUS, Inc. After a day-long review of the safety and efficacy of QNEXA, the advisory panel decided to not recommend approval for the new drug - citing concerns over lack of any two-year data regarding possible side effects of the drug. TOS Advocacy Task Force Member Dr. Caroline Apovian submitted a statement for the record and also spoke during the public meeting where she urged the FDA to help in finding safe and effective medications for obesity management.

Read TOS's response to the FDA Hearing

(Please note: External Links are provided as a courtesy. The Obesity Society is not responsible for the content on sites accessed through external links.)

clinician directory


obesity links


300x250 websitebanner